FRG1P is localised in the nucleolus, Cajal bodies, and speckles

S van Koningsbruggen, R W Dirks, A M Mommaas, J J Onderwater, G Deidda, G W Padberg, R R Frants, S M van der Maarel


The highly conserved facioscapulohumeral muscular dystrophy (FSHD) region gene 1 (FRG1) was initially cloned as candidate gene of unknown function for FSHD. To explore the biological function of the FRG1 protein (FRG1P), we studied its cellular localisation in untransfected and FRG1 transfected cell lines. In interphase cells, FRG1P is localised in the dense structures of the nucleolus, in Cajal bodies, and in 60–80% of cells in nuclear speckles. A time course study revealed that FRG1P accumulates in nuclear speckles before its appearance in nucleoli, whereas the localisation in Cajal bodies remains unchanged, as does the localisation of NHPX protein. In accordance with the presence of FRG1P in these nuclear structures, transcription inhibition experiments showed an effect of RNA polymerases I and II on the localisation of FRG1P. Finally, by deletion of the predicted nuclear localisation signals of FRG1P, we demonstrated that both signals are necessary for this subnuclear localisation.

FRG1P is an attractive candidate for the pathogenesis of FSHD because of its high evolutionary conservation; its transcriptional deregulation in FSHD; and its colocalisation with proteins that are defective in the neuromuscular disorders oculopharyngeal muscular dystrophy (OPMD) and spinal muscular atrophy (SMA).

FRG1 (FSHD Region Gene 1, accession number L76159) was isolated as the first candidate gene for the autosomal dominant myopathy, facioscapulohumeral muscular dystrophy, in 1996. FSHD is primarily characterised by progressive weakness and atrophy of the facial, upper arm, and shoulder muscles. The FSHD locus on 4q35 contains a polymorphic repeat array consisting of 3.3 kb repeated elements (D4Z4). In control individuals, this array may vary between 11–100 units, whereas FSHD patients carry 1–10 units on one of their chromosomes 4, owing to the deletion of an integral number of D4Z4 units. It is becoming increasingly evident that FSHD is caused by a local chromatin alteration, in which contraction of the D4Z4 repeat array results in the transcriptional deregulation of genes located on 4q35 (position effect). Indeed, Gabellini et al recently claimed evidence for transcriptional upregulation of genes close to the repeat in FSHD muscle, including FRG1. In cultured cells, a transcriptional repressor complex binds to D4Z4, and partial loss of this complex leads to transcriptional upregulation of at least one 4qter gene, as observed in FSHD muscle. New expression data based on quantitative RT-PCR suggest that the expression of the 4q35 copy of FRG1 is in fact changed, although the nature of the deregulation is still controversial.

FRG1P is highly conserved in vertebrates and non-vertebrates; the human protein is 97% identical to the murine protein and 46% identical to its orthologue in C elegans. Database searches have identified potential orthologues in—for example—Drosophila, tomato, Xenopus and Schizosaccharomyces pombe. As a result of multiple ectopic duplications, in humans FRG1 belongs to a multigene family, with copies on many different chromosomes. The ancestral copy is located on chromosome 4q35, and is demonstrably transcribed in all tissues tested. Additionally, this chromosome 4 copy of FRG1 is deregulated in FSHD muscle.

The FRG1 transcript is 1042 bp in length, and is distributed over nine exons encoding an open reading frame (ORF) of 258 amino acid residues. This ORF is coding for a 30 kDa protein, which does not show homology to known proteins. Computer algorithms predict an amino terminal nuclear localisation signal (NLS) and a carboxy terminal bipartite (BP) nuclear localisation signal in FRG1P. In fact, the amino terminal signal consists of two NLS motifs, each four residues in size. Moreover, an imperfect lipocalin motif is predicted, which is involved in transport of hydrophobic particles.

Despite its impressive conservation during evolution, indicating a fundamental function, little is known about the role of FRG1P. To obtain more insight into the biological function of FRG1P and its putative involvement in FSHD pathogenesis, we used immunological and GFP based techniques to study its subcellular localisation during different cell stages in untransfected and transfected cell lines. These studies demonstrate that FRG1P colocalises with PABPN1 and SMN1, both involved in related neuromuscular disorders.

MATERIALS AND METHODS
FRG1 fusion and deletion constructs
The ORF of FRG1 was amplified in 30 cycles from fibroblast cDNA using the primers 5'-CCGAGCTCATGGCCGAGTACTCC and 5'-CATTTCAGATCGATGGCTTTTC-3',
and cloned in the TA cloning vector (Invitrogen, Carlsbad, CA, USA), which was subsequently used for all cloning strategies. Different tags were fused to FRG1P to control their effects on the localisation. A FLAG tag (pSuperach-vector) and a vesicular stomatitis tag (VSV, pSG8-vector) were fused to the amino terminal end of FRG1P, to obtain pSG8VSV-FRG1 and pSC-FRG1, respectively. Additionally, the enhanced green fluorescent protein (EGFP, Clonetech, Palo Alto, CA, USA) was fused both to the amino and the carboxy terminal ends of FRG1P (pEGFP-FRG1).

All deletion constructs were derived from pSG8VSV-FRG1. The Δ1 construct, FRG1 without NLS, was obtained by deletion of amino acid 4–81. Subsequently, the Δ2 construct, FRG1 without BP, and the Δ3 variant, FRG1 without NL and BP signals, were generated by deletion of amino acid 232–257 or 4–81, and 232–257, respectively. Finally, the Δ4 deletion construct, missing amino acid 47–231, contained only the NLS and the BP sequences.

All constructs were sequence verified using the BigDye terminator sequencing kit (Perkin Elmer; Foster City, CA, USA) and analysed on an ABI377 (Perkin Elmer). Extensive cloning strategies are available on request.

Cell culture
COS cells, human rhabdomyosarcoma cell line TE671 (gift from Dr A Belayew, Mons, Belgium), and the osteosarcoma cell line U2OS were maintained in DMEM without phenol red (GIBCO Invitrogen, Breda, Netherlands, or GIBCO-BRL), L-glutamine (2 mM, GIBCO-BRL), glucose (100x, GIBCO-BRL), and penicillin–streptomycin (100 IU/100 µg/ml, GIBCO-BRL). The murine myogenic cell line C2C12 was cultured in the same medium, supplemented with 20% FBS.

COS-1 cells, human rhabdomyosarcoma cell line TE671 (gift from Dr A Belayew, Mons, Belgium), and the osteosarcoma cell line U2OS were maintained in DMEM without phenol red (GIBCO Invitrogen, Breda, Netherlands, or GIBCO-BRL), L-glutamine (2 mM, GIBCO-BRL), glucose (100x, GIBCO-BRL), and penicillin–streptomycin (100 IU/100 µg/ml, GIBCO-BRL). The murine myogenic cell line C2C12 was cultured in the same medium, supplemented with 20% FBS. The cells were cultured in an incubator with 5% CO2 at 37°C.

Transient and stable transfections
Twenty four hours before transient transfections, 1 × 10^5 COS-1, TE671, and U2OS cells, and 2.5 × 10^4 C2C12 cells were seeded per 35 mm culture dish, with or without coverslips (20 × 20 mm). Cells were transfected using Fugene (Roche, Basel, Switzerland), according to the manufacturer’s instructions.

For stable transfections, 7 × 10^3 U2OS cells were seeded in 9 cm dishes and transfected with pEGFP-FRG1, according to the Fugene protocol. Twenty four hours after transfection, cells were put under selection by adding 400 µg/ml Geneticin (G418, GIBCO-BRL). After two to three weeks, genetic resistant colonies were selected and screened for the expression of EGFP-FRG1P. Clones 3 and D were used for further experiments.

For the time course experiment, COS-1 cells were transiently transfected with pEGFP-FRG1 and fixed at every two hours from one to 19 hours, and at 24, 48, 72, and 120 hours. After staining with appropriate CajaI body and speckle markers, 50 cells at each time point were analysed for the localisation of EGFP-FRG1P.

Total cell lysates and nuclear extracts
U2OS cells were lysed with Laemmli buffer to obtain total cell lysates. Nuclear and cytoplasmic extracts were obtained from 2 × 10^7 untransfected and EGFP-FRG1P stably transfected U2OS cells (clones 3 and D), as previously described.44 Protein concentrations were measured using the Pierce kit (Pierce, Rockford, IL, USA), according to the manufacturer's instructions.

Antibodies
Two polyclonal rabbit anti-FRG1P sera were raised against recombinant FRG1P (124987 and 124988). Both were able to detect overexpressed FRG1P in immunological assays. Anti-serum 124987 performed better than 124988 and was therefore used in all subsequent experiments. Anti-FRG1P serum was used in 1:1000 dilution on Western blot and for immunocytochemistry, and the affinity purified rabbit anti-FRG1P antibody (derived from anti-serum 124987) was used in 1:10 dilution for all applications.

For immunocytochemistry and immunoblotting, the mouse monoclonal M2 anti-FLAG antibody (Sigma-Aldrich, St Louis, MO, USA) and P5D4 (gift from Dr J Franssen, Nijmegen, Netherlands) were used in a dilution of 1:5000 and 1:3000, respectively. Colocalisation studies were performed with mouse anti-fibrillarin (1:5) (gift from Dr KM Pollard, Scripps Institute, San Diego, USA), mouse anti-SC35 (1:300) (Sigma-Aldrich), mouse anti-coilin (1:200) (gift from Dr A I Lamond, Dundee, UK), and mouse anti-PML 5E10 (1:10) (gift from Dr L de Jong, Amsterdam, Netherlands). The purity of the nuclear and cytoplasmatic fractions were confirmed with mouse anti-beta tubulin E7 (DSHB, Iowa, USA) in a dilution of 1:5, and with rabbit anti-PABPN1 (gift from Dr E Wahle, Halle, Germany), in a dilution of 1:200. Rabbit anti-mouse Alexa Fluor 488 (Molecular Probes, Eugene, OR, USA) and goat anti-mouse Alexa Fluor 594 (Jackson Laboratory, West Grove, PA, USA) were used in dilutions of 1:1000 and 1:5000, respectively. Immuno electron microscopy (immunoEM) was performed with P5D4 and rabbit anti-mouse in dilutions of 1:6000 and 1:200, respectively. The antibody complex was detected with protein-A 10 nm gold in a dilution of 1:400.

Protein induction in BL21-CodonPlus (DE3) bacteria
pET28-FRG1(-NLS) induction was performed according to the manufacturer’s instructions (Stratagene, La Jolla, CA, USA). Bacterial cells were dissolved in sonic buffer (300 mM sodium chloride, 50 mM sodium phosphate, pH 8.0) after three hours and lysed using a French press (American Instrument Company, Haverhill, MA, USA). The lysate was centrifuged for 30 minutes at 7000 g, to obtain the soluble FRG1P-NLS fraction in the supernatant.

Antibody affinity purification
The polyclonal rabbit anti-FRG1P serum was incubated with an overdose of soaked ammonium sulphate for 30 minutes on ice, and centrifuged for 12 minutes at 7000 g to remove serum albumin. The pellet was resuspended in 1:3 starting volume of sonic buffer at pH 8.0, with a 1:3 starting volume of soaked ammonium sulphate, and incubated again for 30 minutes on ice. This procedure was repeated twice. Finally, the pellet was resuspended in a 2:3 starting volume sonic buffer at pH 8.0.

HIS-FRG1P(-NLS) bacterial lysates were bound to talon resin (Clontech) according to the manufacturer’s instructions, before the serum and the talon were incubated overnight at 4°C. Anti-FRG1P antibodies were eluted by 6 M guanidine in sonic buffer at pH 8.0. Finally, purified proteins were dialysed against PBS three times for at least one hour each time.

Immunoblotting
Lysates were loaded on a 10% SDS-polyacrylamide gel and blotted onto Hybond-ECL membrane (Amersham, Amersham, UK). Immunoblotting was performed according to standard protocols. The blot was incubated with the primary P5D4 antibody and the secondary goat anti-mouse HRP, for 60 minutes each. Protein bands were visualised using the Amersham ECL kit, according to the manufacturer’s instructions.
Electron microscopy

COS-1 cells were trypsinised, washed in PBS, fixed in 0.1% glutaraldehyde in 0.14 M cacodylate buffer (pH 7.3) for one hour, and processed for immunofluorescence as described elsewhere. Immunolabelling was performed with P5D4, rabbit-antimouse and protein A-10 nm gold.

Transcription inhibition

Transcription in stably transfected FRG1 cell lines was inhibited by actinomycin D (Sigma-Aldrich) at concentrations of 0.04, 0.2, 1, 5, and 20 μg/ml three hours before fixation, or by incubating the cells for 90 minutes or three hours with 5.6-dichlorobenimidazole ribose (DRB) (Sigma-Aldrich) between every step. After incubation with the secondary antibody for one hour, cells were washed twice in PBS, dehydrated in a graded ethanol series, and mounted in DAPI (50 ng/μl) vectashield (Vector Laboratories, Barlingame, CA, USA). Final preparations were analysed with a Leica Aristoplan fluorescence microscope, and images were obtained using Cytovision (Applied Imaging, Santa Clara, CA, USA) digital system.

Figure 1

Western blot analysis of total (T), nuclear (N), and cytoplasmic (C) extracts of untransfected (U) and EGFP-FRG1P stably transfected (3 and D) U2OS cell lines. The rabbit anti-FRG1P antisemur, but not the preimmune serum, detected FRG1P in nuclear extracts and at very low levels in total cell lysates upon longer exposure. The lower panels show the same extracts stained with rabbit anti-GFP, rabbit anti-PABPN1 (nuclear), and mouse anti-tubulin (cytoplasmic).

RESULTS

The endogenous FRG1P is located in the nucleus

Total, nuclear, and cytoplasmic extracts of untransfected and two EGFP-FRG1P stably transfected U2OS cell lines (3 and D) were analysed on Western blot to demonstrate that the endogenous FRG1P is localised in nuclei, in accordance with the predicted NLS and BP signals. As expected, beta tubulin and PABPN1 were predominantly detected in the cytoplasmic and nuclear fractions, respectively (fig 1). The endogenous FRG1P was clearly detected in the nuclear fractions, but not in the cytoplasmic fractions of each cell line. At a very low level, the postimmune anti-FRG1P serum also detected FRG1P in total cell lysates (fig 1). As expected, the preimmune serum did not show reactivity for FRG1P (fig 1).

In addition, EGFP-FRG1P was clearly detected with both the postimmune anti-FRG1P serum and the anti-GFP antibody, and was mainly restricted to the nuclear extracts of both stably transfected cell lines (fig 1).

Since the antiserum failed to visualise the endogenous FRG1P in immunofluorescent assays of cell lines and tissue, we could not study endogenous FRG1P in muscle of patients and controls. Therefore, transient and stable transfections were performed to study its subcellular localisation in more detail.

The subcellular localisation of FRG1P fusion constructs

Initially, all full length expression constructs of the FRG1P fusion proteins were transiently transfected in different cell types: COS-1, U2OS, and the myogenic cell lines C2C12 and TE671. Since all these transient transfections showed a similar distribution of the FRG1 fusion protein, EGFP-FRG1 was subsequently stably transfected in U2OS cells. All cell lysates were analysed on Western blot to confirm expression of the full length FRG1P fusion proteins. Both the anti-tag antibodies and the affinity purified polyclonal anti-FRG1P antibody clearly detected the fusion proteins of the correct sizes ( fig 1). In stably transfected cells, immunofluorescent assays showed FRG1P to be localised in nucleoli and in small nuclear bodies during interphase. A diffuse nuclear localisation was also apparent (fig 2). In mitotic cells, which were devoid of nuclei, FRG1P was localised throughout the whole cell. Identical localisation signals were obtained after transient transfections, using different expression constructs in various cell lines. Remarkably, in approximately 60–80% of the transiently transfected cells, FRG1P was also localised in a nuclear speckle-like structure. The subnuclear localisation was consistent in all cells studied, even in cells expressing the transgene at very low, presumably close to endogenous, levels.

FRG1P, a predominantly nucleolar protein, is associated with dense nucleolar structures

The nucleolar localisation was evident from negative DAPI staining, and confirmed by double immunostaining with the known nucleolar protein fibrillarin (fig 2A–D). Furthermore, immunoEM showed a clear labelling of the nucleolus in COS-1 cells transfected with pSG8VSV-FRG1 (fig 3A). FRG1P localisation was restricted to the dense structures of the nucleolus (dense fibrillar component and granular component) (fig 3B).

FRG1P is also detected in Cajal bodies and in nuclear speckles

Double staining of FRG1P and coillin, a Cajal body marker, identified the small FRG1P-positive nuclear structures as Cajal bodies (fig 2E–H). Such a colocalisation was not seen for promyeloctytic leukaemia (PML) bodies using antibodies specific for PML protein (data not shown). The additional speckle-like structures in which FRG1P was found following transient transfections were defined as splicing factors containing domains, or nuclear speckles, by double staining with the splicing factor SC35 (fig 2I–L).

Localisation of nuclear speckles precedes nucleolar staining

To study the trafficking of FRG1P between these nuclear components, COS-1 cells were transiently transfected with pEGFP-FRG1 and fixed at intervals of two hours from one to 19 hours, and at 24, 48, 72, and 120 hours after transfection. Seven hours after transfection, EGFP-FRG1P was detected in the nuclear speckles and in Cajal bodies, which was again confirmed by double staining with antibodies against SC35 and coillin, respectively. After nine hours, FRG1P was also...
slightly expressed in the nucleoli of some cells. Over time, the amount of cells expressing FRG1P in nucleoli increased, whereas the speckle staining decreased. However, the speckle localisation did not completely disappear in all cells. In contrast, the Cajal body staining remained stable over time. The dynamic localisation of FRG1P is shown in fig 4.

Figure 2 Stable transfections of EGFP-FRG1 in U2OS cells (A–H), and a transient transfection of EGFP-FRG1 in COS-1 cells (I–L). (A), (E), and (I), DAPI staining demonstrating the nucleus with a negative staining of the nucleoli. (B, F), Stable U2OS cells expressing EGFP-FRG1P. (C) Nucleolar and Cajal body localisation of fibrillarin. (D) Merging B and C shows colocalisation in nucleoli and Cajal bodies. (G) Cajal body localisation of coilin. (H) Merging both images F and G shows colocalisation in Cajal bodies. (J) EGFP-FRG1P expression in transiently transfected COS-1 cells. (K) Speckle localisation of SC35. (L) Merging (J) and (K) shows colocalisation in the nuclear speckles. Bar = 10 μm.

Figure 3 Electron micrographs of ultrathin cryosections of transiently transfected COS-1 cells. VSV-FRG1P was visualised by P5D4 antibody and 10 nm colloidal gold. (A) FRG1P labelling is restricted to the nucleoli. (B) A higher magnification shows that FRG1P is localised to the dense areas of the nucleoli (DFC and GC). Bar = 0.5 μm.
FRG1 has two nuclear localisation signals

To test the functionality of the putative nuclear signals in FRG1P, deletion constructs of pSG8VSV-FRG1 were generated (fig 5A). These constructs were either missing the amino terminal NLS (Δ1) or the carboxy terminal BP (Δ2) or both signals (Δ3). In a fourth construct (Δ4), the region between both signals was removed. The protein sizes of the different deletion constructs were analysed by Western blot and proved to be correct (fig 5B). Transient transfection of these deletion constructs in COS-1 cells showed that Δ1, without NLS, displayed a diffuse nuclear and cytoplasmic staining (fig 5C). The Δ2 construct, lacking the BP, revealed a nuclear speckle localisation (fig 5D), which was confirmed by colocalisation with SC35 (data not shown). Deletion of the NLS and BP signals (Δ3) resulted in a diffuse nuclear and cytoplasmic localisation (fig 5E). Finally, the construct containing only the NLS and the BP (Δ4) was localised in nucleoli and speckles, like the full length FRG1 construct (fig 5F).

Transcription inhibition suggests a role for FRG1P in RNA biogenesis

To study the role of FRG1P in RNA processing, transcription inhibition experiments were performed in U2OS cells stably transfected with EGFP-FRG1. Addition of low concentrations of actinomycin D (0.02 and 0.04 µg/ml) resulted in accumulation of EGFP-FRG1P at the nucleolar periphery, but the localisation of FRG1P in the Cajal bodies remained unchanged (fig 6A–B). Treatment with high concentrations of actinomycin D (5 and 20 µg/ml) resulted in accumulation of EGFP-FRG1P at the nucleolar periphery, as described for collagen, fibrillarin, and GAR1.22 23 FRG1P is also localised in Cajal bodies, which are nuclear structures of 0.2–1.5 µm in size and vary in number from 1–10 per cell. Cajal bodies contain a variety of components, including splicing snRNPs and small nuclear RNPs (snoRNPs), and human autoantigen P80-collin.24 25 They are thought to be involved in post-transcriptional modification of spliceosomal snRNAs and snoRNAs19 26–28 and in shuttling snoRNPs from the nucleoplasm to the nucleolus.29 30 As expected, transcription inhibition of RNA polymerase II (pol II) with high concentrations of actinomycin D or DRB redistributes FRG1P from nucleoli and Cajal bodies to the nucleoplasm.

DISCUSSION

FRG1 was isolated as a positional candidate gene for the autosomal dominant myopathy FSHD, but the function of the encoded protein product is still unknown and a role in FSHD pathogenesis is not yet established.1 Nevertheless, the presence of highly conserved FRG1 homologues in vertebrates and non-vertebrates is suggestive of an essential role in evolution.6 As a first step towards understanding the function of the encoded protein FRG1P, we studied its subcellular localisation in more detail. FRG1P probably is not an abundant protein, since it can only be detected at very low levels on Western blots of total lysates. Since immunofluorescent assays failed to detect FRG1P in different cell lines and muscle sections of patients and controls, we studied its subcellular localisation in cell lines transfected with FRG1 using immunocytochemistry and immunoEM. All our studies demonstrated that FRG1P is localised in nucleoli and Cajal bodies, as evidenced by colocalisation experiments with fibrillarin and collin. In 60–80% of the transiently transfected cells, FRG1P was also localised in the nuclear speckles, demonstrated by a double staining with SC35.

The membraneless nucleolus is involved in rRNA processing, ribosome assembly,14–17 maturation of small nuclear ribonucleoproteins (snRNPs),18 19 and nuclear export of a subset of mRNAs.18 20 Our immunoEM studies provided evidence that FRG1P is localised in the dense structures of the nucleolus—that is, the dense fibrillar component and the granular component—which may be indicative of a role in processing of pre-rRNA or in assembly of rRNA into ribosomal subunits.15 17 21 Indeed, low concentrations actinomycin D, affecting RNA polymerase I (pol I), cause accumulation of EGFP-FRG1P at the nucleolar periphery, as described for coilin, fibrillarin, and GAR1.22 23 FRG1P is also localised in Cajal bodies, which are nuclear structures of 0.2–1.5 µm in size and vary in number from 1–10 per cell. Cajal bodies contain a variety of components, including splicing snRNPs and small nuclear RNPs (snoRNPs), and human autoantigen P80-collin.24 25 They are thought to be involved in post-transcriptional modification of spliceosomal snRNAs and snoRNAs19 26–28 and in shuttling snoRNPs from the nucleoplasm to the nucleolus.29 30 As expected, transcription inhibition of RNA polymerase II (pol II) with high concentrations of actinomycin D or DRB redistributes FRG1P from nucleoli and Cajal bodies to the nucleoplasm.

Lastly, transiently transfected cells revealed the presence of FRG1P in nuclear speckles, which may serve as storage sites for protein splicing factors and snRNPs. They may also coordinate transcription and RNA processing.13 The presence of FRG1P in nuclear speckles after transient transfection could be the result of elevated FRG1P expression. Conversely, the absence of FRG1P in the speckle domains in stably transfected cells is a reflection of low expression.

Interestingly, a novel nucleolar pathway was recently described, in which newly synthesised NHPX protein was localised in the nuclear speckles before accumulation in nucleoli, whereas the Cajal body localisation remained unchanged.32 The human NHPX protein is a homologue of NHP2p and orthologue of Snu13p, both from Saccharomyces cerevisiae.33–35 NHPX was demonstrated to be involved both in late stage spliceosome assembly and in rRNA cleavage/modification by binding to U4 snRNA and box C/D snoRNAs, respectively.36 37 Our time course experiment also demonstrated that the nucleolar localisation of FRG1P was preceded by a transient speckle accumulation, whereas this protein was expressed in Cajal bodies at all time points. Therefore, the speckle localisation of FRG1P might well be caused by an overload of the same pathway as described for NHPX. After acute overexpression, FRG1P can probably not be transported far enough from the speckles and therefore accumulates. In the light of these results, we hypothesise that, like NHPX, newly synthesised endogenous FRG1P is localised in speckles and Cajal bodies, whereas the mature protein is present in nucleoli and Cajal bodies.

In accordance with its localisation, two nuclear localisation signals were predicted in FRG1P, an aminoterminal NLS
(KKKK at position 22–25 and KKRK) and a carboxyterminal BP signal (amino acids 235–251). No specific nucleolar localisation (NoLS) signals have been described, but probably a long array of basic amino acids flanked by basic amino acids, RXXR motifs (in which the X is preferably an argine or leucine), or RGG motifs, may act as NoLS. The basic amino acid arrays in FRG1P may thus act as NLS and NoLS. By deletion of either or both of the nuclear localisation signals, we showed that the NLS alone was sufficient for a nuclear localisation of FRG1P, but both NLS and BP were necessary for nucleolar localisation.

The subcellular localisation of FRG1P and its redistribution upon transcription inhibition suggest a possible role in rRNA or mRNA processing. This is substantiated by the detection of FRG1P in a large scale human spliceosome analysis and by the coordinate expression of FRG1P with other proteins involved in ribosomal and mRNA biogenesis in C. elegans.

Remarkably, two other neuromuscular disorders are caused by defects in proteins involved in RNA biogenesis. First, the late onset dominant myopathy OPMD typically presents, like FSHD, with a non-limb-girdle phenotype. OPMD is caused by a moderate alanine expansion in the N-terminus of PABPN1, leading to aggregation of PABPN1 in intranuclear filamentous inclusions in a subset of muscle nuclei. In the nucleus, PABPN1 is localised in speckles and nucleoli, where it stimulates and controls the synthesis of poly(A) tails of pre-mRNA. Although these aggregates in OPMD show many parallels with those caused by polyglutamine expansions, impaired mRNA biogenesis in OPMD cannot be excluded, since the N-terminus of PABPN1 is essential for the stimulation of poly(A) polymerase and it has been demonstrated that these aggregates sequester poly(A) RNA.

Secondly, SMA is caused, in many cases, by disruption of the telomeric copy of the duplicated SMN genes. The SMN...
Our research was funded by the Princess Beatrice Foundation, the Muscular Dystrophy Association USA, the Dutch FSHD Foundation, the National Institutes of Health of the European Union, and the FSH Society, USA.

Authors’ affiliations
S van Koningsbruggen, R R Frants, S M van der Maarel, Department of Human Genetics, Leiden University Medical Center, Netherlands
R W Dirks, Department of Molecular Cell Biology, Leiden University Medical Center, Netherlands
A M Moomaas, J J Onderwater, Centre for Electron Microscopy, Leiden University Medical Center, Netherlands
G Deidda, Institute of Cell Biology, CNR, Rome, Italy
G W Pardos, Department of Neurology, University Medical Center Nijmegen, Netherlands

Correspondence to: S M van der Maarel, Leiden University Medical Center, MGC-Department of Human Genetics, Wassenaarseweg 72, 2333 AL Leiden, Netherlands; maarel@lumc.nl

REFERENCES
of bipartite nuclear targeting sequence.


FRG1P is localised in the nucleolus, Cajal bodies, and speckles

S van Koningsbruggen, R W Dirks, A M Mommaas, J J Onderwater, G Deidda, G W Padberg, R R Frants and S M van der Maarel

*J Med Genet* 2004 41: e46
doi: 10.1136/jmg.2003.012781

Updated information and services can be found at:
http://jmg.bmj.com/content/41/4/e46

**References**

This article cites 54 articles, 25 of which you can access for free at:
http://jmg.bmj.com/content/41/4/e46#BIBL

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**

Articles on similar topics can be found in the following collections

- Muscle disease (146)
- Neuromuscular disease (257)
- Motor neurone disease (19)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/